Hennessey J V, Jackson I M
Division of Endocrinology, Brown University School of Medicine/Rhode Island Hospital, Providence 02903, USA.
Baillieres Clin Endocrinol Metab. 1995 Apr;9(2):271-314. doi: 10.1016/s0950-351x(95)80338-6.
Pituitary adenomas are frequently encountered, benign intracranial tumours. Clinically classified according to their capacity to produce and secrete hormones, pituitary tumours are diagnosed from the clinical manifestations and biochemical findings of specific pituitary hormone overproduction or of impaired pituitary function due to pressure on normal pituitary cells, the pituitary stalk or the hypothalamus. Additionally, the tumour may result in neurological manifestations due to its effect as an intracranial space-occupying lesion. Pituitary adenomas may present acutely with pituitary apoplexy after intrapituitary haemorrhage or infarction. The subsequent hypofunction of the pituitary with concomitant neurological sequelae of an expanding intracranial mass are often associated with excruciating headache, diplopia and visual field defects. Gradually developing neurological deficits or secondary endocrine failure over several years may precede the recognition of non-secretory tumours (30-40% of pituitary adenomas) as well as some of the hormone-producing adenomas, especially when they expand beyond the confines of the sella turcica. Asymptomatic masses occur in the pituitary in 5-27% of unselected autopsy series. About 10-20% of pituitaries imaged as part of a brain study contain lesions 'consistent with a pituitary adenoma', with about half being pituitary adenomas ('incidentalomas'). Many advocate screening such cases for a wide spectrum of pituitary function abnormalities. Clinical judgement should be utilized to determine the extent of the work-up and the frequency of follow-up. Acromegaly, a clinical syndrome caused by excess growth hormone secretion, accounts for one-sixth of resected pituitary tumours. This disorder leads to chronic progressive disability and a shortened life span, with approximately 50% of untreated acromegalic patients experiencing premature death. The prevalence of acromegaly has been estimated to range from 50 to 70 per million, with the age of diagnosis usually between the third and fifth decades. Conditions associated with acromegaly include glucose intolerance, diabetes mellitus, lipid abnormalities, cholelithiasis, goitre, and hyperthyroidism, respiratory complications, hypertension, cardiovascular disease, and calcium metabolism abnormalities. An association between acromegaly and cancer, especially of the colon, is now recognized. Epidemiological series have indicated that cancer of the colon, breast and other types of malignancy are a cause of death with increased frequency in acromegalics compared with expected rates. Hypopituitary symptoms secondary to the mass effect of macroadenomas in acromegalic patients are common. Among premenopausal women, menstrual irregularities and galactorrhoea have been reported in 40-70%, while more than half of the men complain of impotence and decreased libido.(ABSTRACT TRUNCATED AT 400 WORDS)
垂体腺瘤是常见的颅内良性肿瘤。根据其产生和分泌激素的能力进行临床分类,垂体肿瘤可根据特定垂体激素分泌过多或由于对正常垂体细胞、垂体柄或下丘脑的压迫导致垂体功能受损的临床表现和生化检查结果来诊断。此外,肿瘤作为颅内占位性病变,可能导致神经症状。垂体腺瘤可在垂体出血或梗死导致垂体卒中后急性起病。随后垂体功能减退并伴有颅内肿块扩大的神经后遗症,常伴有剧烈头痛、复视和视野缺损。在数年中逐渐出现的神经功能缺损或继发性内分泌功能衰竭,可能先于非分泌性肿瘤(占垂体腺瘤的30% - 40%)以及一些分泌激素的腺瘤被发现,尤其是当它们超出蝶鞍范围时。在未选择的尸检系列中,5% - 27%的垂体存在无症状肿块。在脑部检查中成像的垂体中,约10% - 20%有“符合垂体腺瘤”的病变,其中约一半是垂体腺瘤(“偶发瘤”)。许多人主张对这类病例进行广泛的垂体功能异常筛查。应运用临床判断来确定检查的范围和随访的频率。肢端肥大症是一种由生长激素分泌过多引起的临床综合征,占切除的垂体肿瘤的六分之一。这种疾病导致慢性进行性残疾和寿命缩短,约50%未经治疗的肢端肥大症患者过早死亡。肢端肥大症的患病率估计为每百万人口50至70例,诊断年龄通常在第三和第五个十年之间。与肢端肥大症相关的疾病包括糖耐量异常、糖尿病、脂质异常、胆石症、甲状腺肿和甲状腺功能亢进、呼吸并发症、高血压、心血管疾病以及钙代谢异常。现在已认识到肢端肥大症与癌症,尤其是结肠癌之间的关联。流行病学系列研究表明,与预期发生率相比,肢端肥大症患者中结肠癌、乳腺癌和其他类型恶性肿瘤导致死亡的频率增加。肢端肥大症患者中,大腺瘤的占位效应引起的垂体功能减退症状很常见。在绝经前女性中,40% - 70%有月经不调和溢乳的报道,而超过一半的男性主诉阳痿和性欲减退。(摘要截选至400字)